Multiple sclerosis (MS) is best known for the physical symptoms it can cause, such as numbness, weakness, spasticity, and difficulty walking. But this autoimmune disease of the central nervous system ...

The dazzling 36-month clinical data announced by uniQure (NASDAQ: QURE) showing a significant slowing of Huntington’s disease (HD) progression in patients treated with its gene therapy candidate ...

eMultiple Sclerosis Centre and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, ...

UniQure shares tripled, to $41.27, in early Wednesday trading after the company said it had positive topline results for a Phase I/II study of AMT-130 for the treatment of Huntington's disease, and ...

~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external ...

Credit: Getty Images Researchers identified clinical and magnetic resonance imagining predictors of fatigue worsening in patients with multiple sclerosis. Worsening fatigue in patients with multiple ...

This important manuscript presents a novel application of the SANDI (Soma and Neurite Density Imaging) model to study microstructural alterations in the basal ganglia of individuals with Huntington's ...

Having better physical performance is associated with higher cognitive function in people with multiple sclerosis (MS), particularly among those with more disability, a study finds. Disability levels, ...

Cognitive impairment is increasingly recognized in patients with cerebral venous congestion (CVC), yet the cognitive tools used are largely adapted from stroke and dementia research. This review ...

PTC Therapeutics is a commercial stage biotechnology firm. Its last Phase 2 trial, investigating PTC518 in Huntington's disease, released mixed results about the drug efficacy. We think a Phase 3 ...

COGNITIVE decline in relapsing-remitting multiple sclerosis (RRMS) can progress independently of both relapses and MRI-detected disease activity, challenging traditional methods of monitoring MS ...